BRPI0518619A2 - mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica - Google Patents

mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica

Info

Publication number
BRPI0518619A2
BRPI0518619A2 BRPI0518619-6A BRPI0518619A BRPI0518619A2 BR PI0518619 A2 BRPI0518619 A2 BR PI0518619A2 BR PI0518619 A BRPI0518619 A BR PI0518619A BR PI0518619 A2 BRPI0518619 A2 BR PI0518619A2
Authority
BR
Brazil
Prior art keywords
combination
pharmaceutical
composition
treating cancer
mammal
Prior art date
Application number
BRPI0518619-6A
Other languages
English (en)
Inventor
Claudine Elvire Marie Bruck
Catherine Marie Ghislaine Gerard
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0518619A2 publication Critical patent/BRPI0518619A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MÉTODO DE TRATAR CÂNCER EM UM MAMÍFERO, COMBINAÇçO FARMACÊUTICA, USO DE UMA COMPOSIÇçO OU COMBINAÇçO FARMACÊUTICA E COMPOSIÇçO IMUNOGÊNICA. Um método de tratar câncer é descrito compreendendo administração de uma 4-quinazolinamina e uma vacina tendo como alvo a molécula de HER-2/neu, assim como uma combinação farmacêutica compreendendo 4-quinazolinamina e uma vacina tendo como alvo a molécula de HER-2/neu.
BRPI0518619-6A 2004-12-10 2005-12-08 mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica BRPI0518619A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0427131.8A GB0427131D0 (en) 2004-12-10 2004-12-10 Novel combination
PCT/EP2005/013409 WO2006061253A2 (en) 2004-12-10 2005-12-08 Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy

Publications (1)

Publication Number Publication Date
BRPI0518619A2 true BRPI0518619A2 (pt) 2008-11-25

Family

ID=34073534

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518619-6A BRPI0518619A2 (pt) 2004-12-10 2005-12-08 mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica

Country Status (15)

Country Link
US (1) US20100028414A1 (pt)
EP (1) EP1824509A2 (pt)
JP (1) JP2008523017A (pt)
KR (1) KR20070098857A (pt)
CN (1) CN101115499A (pt)
AU (1) AU2005313439A1 (pt)
BR (1) BRPI0518619A2 (pt)
CA (1) CA2589981A1 (pt)
GB (1) GB0427131D0 (pt)
IL (1) IL183448A0 (pt)
MA (1) MA29133B1 (pt)
MX (1) MX2007006927A (pt)
NO (1) NO20072668L (pt)
RU (1) RU2007120462A (pt)
WO (1) WO2006061253A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7972602B2 (en) * 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
CA2675366A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
KR20110044905A (ko) * 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
WO2010023216A1 (en) 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccine
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
AU2016232834B2 (en) * 2015-03-19 2020-01-02 Aerovironment, Inc. Mounting system for mechanical-shock resistant printed circuit board (PCB)
RU2603943C1 (ru) * 2016-02-01 2016-12-10 Индивидуальный предприниматель Михайлов Олег Ростиславович КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ N-{3-ХЛОР-4-[(3-ФТОРБЕНЗИЛ)ОКСИ] ФЕНИЛ}-6-[5-({[2-(МЕТАНСУЛЬФОНИЛ)ЭТИЛ]АМИНО}МЕТИЛ)-2-ФУРИЛ]-4-ХИНАЗОЛИНАМИНА БИС (4-МЕТИЛБЕНЗОЛСУЛЬФОНАТА) МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
US20210121518A1 (en) * 2018-02-15 2021-04-29 Board of Supervisors for the University of Louisiana System Her2-targeted peptidomimetics grafted onto multicyclic peptide scaffolds and methods and uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
WO2000044899A1 (en) * 1999-01-29 2000-08-03 Corixa Corporation Her-2/neu fusion proteins
CA2413134C (en) * 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents

Also Published As

Publication number Publication date
NO20072668L (no) 2007-09-04
MX2007006927A (es) 2007-06-26
CN101115499A (zh) 2008-01-30
WO2006061253A2 (en) 2006-06-15
MA29133B1 (fr) 2008-01-02
WO2006061253A3 (en) 2006-11-16
RU2007120462A (ru) 2009-01-20
US20100028414A1 (en) 2010-02-04
IL183448A0 (en) 2007-09-20
CA2589981A1 (en) 2006-06-15
KR20070098857A (ko) 2007-10-05
EP1824509A2 (en) 2007-08-29
JP2008523017A (ja) 2008-07-03
GB0427131D0 (en) 2005-01-12
AU2005313439A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
TW200612987A (en) Combination treatment for non-hematologic malignancies
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BRPI0912411A8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
HUS1700012I1 (hu) Bruton-tirozinkináz inhibitorok
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
CY1111177T1 (el) Ενωση φαινοθειαζινιου για επουλωση τραυματων
BRPI0508390B8 (pt) uso de um anticorpo antagonista anti-ngf, bem como kit e composição farmacêutica para tratamento de dor de câncer de osso
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
NO20075136L (no) Nye liposompreparater
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
BRPI0418157A (pt) terapêutica de tumores alogênicos
EP1605847A4 (en) Antibody-targeted photodynamic therapy
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
NO20072668L (no) Ny kombinasjon
DE60019947D1 (de) Vorbeugung von kolorektalkrebs
BRPI0510062A (pt) derivados de antraciclina
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
CR10486A (es) Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico
BR112012013719A2 (pt) uso de transferrina no tratamento de ß-talassemias

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.